ALISO VIEJO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Needham Healthcare Conference.
RxSight’s management is scheduled to participate in a fireside chat on Wednesday, April 19, 2023, at 11:15 a.m. Pacific Time / 2:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery enabling doctors to customize and deliver high-quality of vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley Thunen
RxSight, Inc.
949-521-7830
sthunen@rxsight.com
Investor Relations Contact:
ir@rxsight.com
| Last Trade: | US$14.95 |
| Daily Change: | 0.23 1.56 |
| Daily Volume: | 915,490 |
| Market Cap: | US$602.480M |
February 25, 2025 January 12, 2025 January 02, 2025 November 07, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
